Cassava Sciences, Inc.

NasdaqCM:SAVA Voorraadrapport

Marktkapitalisatie: US$206.6m

Cassava Sciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Cassava Sciences heeft een totaal eigen vermogen van $166.6M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $223.8M en $57.1M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$148.98m
AandelenUS$166.64m
Totaal verplichtingenUS$57.11m
Totaal activaUS$223.75m

Recente financiële gezondheidsupdates

Recent updates

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh

Nov 07

Cassava Sciences: Turning The Corner Into A Brick Wall

Jul 24

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Oct 17
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Jul 04
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Mar 05
We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Nov 19
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Oct 13

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Sep 29

Cassava Sciences: Trying To Manage Expectations

Sep 21

Cassava Sciences reaches over five-month high on rising volumes

Sep 09

Cassava Sciences Looks As Good Of A Purchase As Ever

Sep 03

Cassava Sciences stock jumps 10% after director buys $860K shares

Aug 26

Cassava Sciences rally continues as stock up 39%

Aug 17

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

Aug 11

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

Aug 03

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Aug 03
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Jul 27

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Jun 10

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

May 31

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

Apr 19
Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

3 Key Points To Remember About Cassava Sciences

Apr 07

Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences

Mar 31

Cassava Sciences: Why The Stock Is Rangebound

Feb 28

The FDA Deals Another Blow To Cassava Sciences' Bears

Feb 11

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

Feb 02

INmune Bio, The Biotech In My Stable For After Cassava Sciences

Jan 17

Cassava Sciences, Inc. - The Short Squeeze Has Started

Jan 06

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

Dec 30

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Dec 28
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Cassava Sciences Stock: Here We Go Again

Dec 21

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

Dec 02

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $202.5M ) SAVA } overtreffen de korte termijn passiva ( $57.0M ).

Langlopende schulden: De kortetermijnactiva SAVA ( $202.5M ) overtreffen de langetermijnschulden ( $80.0K ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: SAVA is schuldenvrij.

Schuld verminderen: SAVA heeft de afgelopen 5 jaar geen schulden gehad.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: SAVA heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: SAVA heeft voldoende kasruimte voor 1.8 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 44.6 % per jaar.


Ontdek gezonde bedrijven